Literature DB >> 11324929

The first description of rheumatoid arthritis. Unabridged text of the doctoral dissertation presented in 1800.

A J Landré-Beauvais.   

Abstract

This unabridged version of the dissertation presented in 1800 by Augustin Jacob Landré-Beauvais for his medical doctorate describes a disease different in many ways from the condition known since Hippocrates as gout. The patients were nine long-term residents of the Salpêtrière hospice in Paris. After reviewing the main features of ordinary or regular gout, Landré-Beauvais points out that the disease he calls "asthenic gout" exhibits several distinctive features, including predominance in women, a chronic course, involvement of many joints from the onset, and a decline in general health. Despite the tentative tone of his title ("Should one recognize...), he clearly is convinced that he is describing an as yet unreported entity, as indicated by the last sentence of his dissertation: "...we must recognize the existence of a new form of gout under the designation primary asthenic gout" And although he stops short of emancipation from the term "gout", which had been used for centuries to designate specific joint manifestations, he makes several keenly discerning observations -- particularly regarding the influence of psychological factors, the need for gentle treatments, and the inappropriateness of bloodletting - thus breaking free from contemporary doctrine. This text is acknowledged as the first description of rheumatoid arthritis. A brief biography of Landré-Beauvais is provided.

Entities:  

Mesh:

Year:  2001        PMID: 11324929     DOI: 10.1016/s1297-319x(00)00247-5

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  17 in total

1.  Nicotinamide Phosphoribosyltransferase in Human Diseases.

Authors:  Li Qin Zhang; Daniel P Heruth; Shui Qing Ye
Journal:  J Bioanal Biomed       Date:  2011-01-07

2.  Historical perspective on the etiology of rheumatoid arthritis.

Authors:  Pouya Entezami; David A Fox; Philip J Clapham; Kevin C Chung
Journal:  Hand Clin       Date:  2011-02       Impact factor: 1.907

3.  The potential of multiple synovial-fluid protein-concentration analyses in the assessment of knee osteoarthritis.

Authors:  Jeffrey B Driban; Easwaran Balasubramanian; Mamta Amin; Michael R Sitler; Marvin C Ziskin; Mary F Barbe
Journal:  J Sport Rehabil       Date:  2010-11       Impact factor: 1.931

Review 4.  Cardiovascular disease in patients with rheumatoid arthritis.

Authors:  Katherine P Liao
Journal:  Trends Cardiovasc Med       Date:  2016-08-03       Impact factor: 6.677

5.  Optimizing Rheumatoid Arthritis Therapy: Using Objective Measures of Disease Activity to Guide Treatment.

Authors:  Gary M Owens
Journal:  Am Health Drug Benefits       Date:  2015-10

6.  Cadmium, one of the villains behind the curtain: has exposure to cadmium helped to pull the strings of seropositive rheumatoid arthritis pathogenesis all along?

Authors:  David Hutchinson
Journal:  Int J Rheum Dis       Date:  2015-06       Impact factor: 2.454

Review 7.  Enigma of IL-17 and Th17 Cells in Rheumatoid Arthritis and in Autoimmune Animal Models of Arthritis.

Authors:  Reka Kugyelka; Zoltan Kohl; Katalin Olasz; Katalin Mikecz; Tibor A Rauch; Tibor T Glant; Ferenc Boldizsar
Journal:  Mediators Inflamm       Date:  2016-01-20       Impact factor: 4.711

Review 8.  Genetics of rheumatoid arthritis susceptibility, severity, and treatment response.

Authors:  Sebastien Viatte; Anne Barton
Journal:  Semin Immunopathol       Date:  2017-05-29       Impact factor: 9.623

Review 9.  Rheumatoid arthritis: Disease or syndrome?

Authors:  Jessica A Stanich; John D Carter; Judith Whittum-Hudson; Alan P Hudson
Journal:  Open Access Rheumatol       Date:  2009-12-08

10.  Discovery of a new class of inhibitors for the protein arginine deiminase type 4 (PAD4) by structure-based virtual screening.

Authors:  Chian Ying Teo; Steven Shave; Adam Leow Thean Chor; Abu Bakar Salleh; Mohd Basyaruddin Bin Abdul Rahman; Malcolm D Walkinshaw; Bimo A Tejo
Journal:  BMC Bioinformatics       Date:  2012-12-13       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.